UPTON, NY – Researchers from the U.S. Department of Energy's Brookhaven National Laboratory (BNL) and BioSurface Engineering Technologies, Inc. (BioSET) have developed a synthetic peptide that enhances the effects of a tissue growth factor known as bone morphogenetic protein 2, or BMP-2. BMPs are a family of proteins in the human body responsible for the proliferation, repair, and differentiation of cells in many tissues, including bone.
The researchers designed one portion of the peptide to target the BMP-2 receptor molecules that occur on the surface of bone-forming stem cells and another portion to interact with BioSET's drug-binding agent HepaSilTM, a heparin-based product. The peptide, called B2A2, is one of a series of synthetic analogs of naturally occurring growth factors being developed in the Brookhaven/BioSET collaboration.
This research is reported in the November 8th online version of the Journal of Bone & Mineral Research.
"Our study shows that a small amount of the peptide that we developed increases the effectiveness of BMP-2 as much as 40 times," said Brookhaven scientist Louis Peña, senior author of the paper. "This peptide unlocks a synergy with BMP-2. In a cell culture model, we used BMP at doses too low to have any observable effect by itself, and the same was true for the B2A2 peptide. But when the two were added together in the same low doses, the cells were strongly triggered to develop into bone-forming cells.
"First-generation BMP-impregnated medical devices are currently used clinically for spine repair and to accelerate the healing of long bones," Peña continued. "These devices show effectiveness in inducing bone repair, but there is concern over the high levels of the growth factors that are currently required. An agent that decreases the amount of BMP needed or one that can recruit the body's own growth factors to be more effective could have a substantial clinical benefit."
The growth factor analogs developed in the Brookhaven/BioSET collaboration are synthetic peptides that are chemically more stable and easier to produce than natural growth factors or growth factors derived by recombinant protein techniques. BioSET has an exclusive license to develop and market these bioactive analogs.
Thomas Roueché, BioSET's president, said, "We are fortunate to enjoy a fruitful collaboration. This class of peptide and others under development supports the concept of design-targeted synthetic peptides for specific tissue regeneration applications. The Brookhaven/BioSET collaboration continues to yield very promising results aimed at replicating human growth factors, and we look forward to further validating the potential of these peptides to enhance the body's healing capacity, especially when combined with orthopedic implants."
He added, "We believe the future of orthopedics will continue evolving towards combination products, such as devices that have been biologically enhanced. For example, approved growth factor-type combination device products are currently valued at over $1.6 billion. Our ability to bring new bioactive peptides into the mix of new product development positions us at the leading edge of an important evolution in orthopedic medicine."
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Most of the things worth doing in the world had been declared impossible before they were done.
~ Supreme Court Justice Louis D. Brandeis